Skip to content

17-247 - IV Iron Therapy vs Placebo in the Treatment of Participants in Heart Failure with Iron Deficiency

Status: open

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Treatment for Heart Failure with Iron deficiency

Contact Us


The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction. 


This trial is sponsored by Luitpold Pharmaceuticals.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.